Christy C. Ong

Christy C. Ong

Auto-generated profile, based on publicly available information

Christy C. Ong

Genentech, Discovery Oncology, South San Francisco, California

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
KSKyung W. Song
Kyung W. Song
COChristy C. Ong
Christy C. Ong
ELEva Lin
Eva Lin
JLJeff Lau
Jeff Lau
NSNicole M. Sodir
Nicole M. Sodir
ADAnwesha Dey
Anwesha Dey
PIK3CA and KRAS are among the most frequently mutated oncogenes and often co-mutated in colorectal cancers. Understanding the impact of KRAS codon–specific mutations on cross-talks between the PI3K and MAPK pathways and response to targeted therapies, such as the p110α-specific inhibitor inavolisib (GDC-0077), is critical for advancing precision oncology. Focusing on colorectal PIK3CA + KRAS co-mutated models, we found that KRASG12D-mutated cells were more sensitive to inavolisib than models with KRASG13D, or other MAPK pathway mutations, even though the PI3K and MAPK pathways were active in both genotypes. In most co-mutated models, regardless of the type of KRAS alteration, the combination of inavolisib with MAPK pathway inhibitors showed synergy in vitro and in vivo. Our work highlights how specific codon substitutions in KRAS differentially toggle pathway activity and alter sensitivity to inavolisib, which could inform whether patients would benefit more from single-agent inavolisib or combination with MAPK pathway inhibitors.

2 December 2025
Verified
Other
Open access
KSKyung W. Song
Kyung W. Song
COChristy C. Ong
Christy C. Ong
ELEva Lin
Eva Lin
JLJeff Lau
Jeff Lau
NSNicole M. Sodir
Nicole M. Sodir
ADAnwesha Dey
Anwesha Dey
Supplemental Figure 4: Combination treatment of inavolisib with cobimetinib is synergistic

2 December 2025
Verified
Other
Open access
KSKyung W. Song
Kyung W. Song
COChristy C. Ong
Christy C. Ong
ELEva Lin
Eva Lin
JLJeff Lau
Jeff Lau
NSNicole M. Sodir
Nicole M. Sodir
ADAnwesha Dey
Anwesha Dey
PIK3CA and KRAS are among the most frequently mutated oncogenes and often co-mutated in colorectal cancers. Understanding the impact of KRAS codon–specific mutations on cross-talks between the PI3K and MAPK pathways and response to targeted therapies, such as the p110α-specific inhibitor inavolisib (GDC-0077), is critical for advancing precision oncology. Focusing on colorectal PIK3CA + KRAS co-mutated models, we found that KRASG12D-mutated cells were more sensitive to inavolisib than models with KRASG13D, or other MAPK pathway mutations, even though the PI3K and MAPK pathways were active in both genotypes. In most co-mutated models, regardless of the type of KRAS alteration, the combination of inavolisib with MAPK pathway inhibitors showed synergy in vitro and in vivo. Our work highlights how specific codon substitutions in KRAS differentially toggle pathway activity and alter sensitivity to inavolisib, which could inform whether patients would benefit more from single-agent inavolisib or combination with MAPK pathway inhibitors.

2 December 2025
Verified
Other
Open access
KSKyung W. Song
Kyung W. Song
COChristy C. Ong
Christy C. Ong
ELEva Lin
Eva Lin
JLJeff Lau
Jeff Lau
NSNicole M. Sodir
Nicole M. Sodir
ADAnwesha Dey
Anwesha Dey
Supplemental Table 2: Cell line properties and inavolisib viability data

2 December 2025
Verified
Other
Open access
KSKyung W. Song
Kyung W. Song
COChristy C. Ong
Christy C. Ong
ELEva Lin
Eva Lin
JLJeff Lau
Jeff Lau
NSNicole M. Sodir
Nicole M. Sodir
ADAnwesha Dey
Anwesha Dey
Supplemental Table 3: Cell line properties and levels of PI3K and MAPK signaling proteins

2 December 2025
Verified
Other
Open access
KSKyung W. Song
Kyung W. Song
COChristy C. Ong
Christy C. Ong
ELEva Lin
Eva Lin
JLJeff Lau
Jeff Lau
NSNicole M. Sodir
Nicole M. Sodir
ADAnwesha Dey
Anwesha Dey
Supplemental Figure 3: GP2d and HCT 116 models expressing exogenous mutant KRAS have different sensitivity to inavolisib